These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38069716)

  • 21. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
    Qin HT; Li HQ; Liu F
    Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia.
    Goutas D; Theocharis S; Tsourouflis G
    Diagnostics (Basel); 2021 Jul; 11(8):. PubMed ID: 34441281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medicinal chemistry advances in targeting class I histone deacetylases.
    Abdallah DI; de Araujo ED; Patel NH; Hasan LS; Moriggl R; Krämer OH; Gunning PT
    Explor Target Antitumor Ther; 2023; 4(4):757-779. PubMed ID: 37711592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors: Potential in cancer therapy.
    Marks PA; Xu WS
    J Cell Biochem; 2009 Jul; 107(4):600-8. PubMed ID: 19459166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HDACs and HDAC Inhibitors in Urothelial Carcinoma - Perspectives for an Antineoplastic Treatment.
    Pinkerneil M; Hoffmann MJ; Schulz WA; Niegisch G
    Curr Med Chem; 2017; 24(37):4151-4165. PubMed ID: 28078999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
    Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
    J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
    Beumer JH; Tawbi H
    Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
    Suraweera A; O'Byrne KJ; Richard DJ
    Front Oncol; 2018; 8():92. PubMed ID: 29651407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylases (HDAC) in physiological and pathological bone remodelling.
    Cantley MD; Zannettino ACW; Bartold PM; Fairlie DP; Haynes DR
    Bone; 2017 Feb; 95():162-174. PubMed ID: 27913271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.
    Venturelli S; Berger A; Böcker A; Busch C; Weiland T; Noor S; Leischner C; Schleicher S; Mayer M; Weiss TS; Bischoff SC; Lauer UM; Bitzer M
    PLoS One; 2013; 8(8):e73097. PubMed ID: 24023672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
    Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
    Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases.
    Yoon S; Eom GH
    Chonnam Med J; 2016 Jan; 52(1):1-11. PubMed ID: 26865995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone deacetylase inhibitors in the treatment of hematological malignancies.
    Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
    Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics.
    McClure JJ; Li X; Chou CJ
    Adv Cancer Res; 2018; 138():183-211. PubMed ID: 29551127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interpreting clinical assays for histone deacetylase inhibitors.
    Martinet N; Bertrand P
    Cancer Manag Res; 2011; 3():117-41. PubMed ID: 21625397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitors as cancer therapeutics.
    Clawson GA
    Ann Transl Med; 2016 Aug; 4(15):287. PubMed ID: 27568481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis.
    Du L; Wang D; Wei X; Liu C; Xiao Z; Qian W; Song Y; Hou X
    BMC Gastroenterol; 2022 Jan; 22(1):29. PubMed ID: 35062876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.